BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 38248108)

  • 1. Counselling Framework for Germline
    Wong SM; Apostolova C; Eisenberg E; Foulkes WD
    Curr Oncol; 2024 Jan; 31(1):350-365. PubMed ID: 38248108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences among a Portuguese cohort of BRCA pathogenic/likely pathogenic variants carriers choosing risk-reducing mastectomy or intensive breast surveillance.
    Torres S; Peleteiro B; Magalhães A; Garrido L; Costa S; Fougo JL
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7529-7538. PubMed ID: 36971799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
    Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
    Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.
    Record SM; Thomas SM; Ntowe K; Chiba A; Plichta JK
    Am J Surg; 2024 Jan; 227():146-152. PubMed ID: 37827871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Decision Making in Genetically High-Risk Women: Quantifying Postoperative Complications and Long-Term Risks of Supplemental Surgery After Risk-Reducing Mastectomy.
    Apostolova C; Ferroum A; Alhassan B; Prakash I; Viezel-Mathieu A; Basik M; Boileau JF; Meterissian S; Wong N; Foulkes WD; Wong SM
    Ann Surg Oncol; 2024 Jan; 31(1):356-364. PubMed ID: 37838650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
    Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
    Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers.
    Stanek K; Zimovjanova M; Suk P; Jonas F; Zimovjanova A; Molitor M; Mestak O
    Aesthetic Plast Surg; 2022 Apr; 46(2):706-711. PubMed ID: 34342702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: Are there factors associated with the choice?
    Manoukian S; Alfieri S; Bianchi E; Peissel B; Azzollini J; Borreani C
    Psychooncology; 2019 Sep; 28(9):1871-1878. PubMed ID: 31264307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
    Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mastectomy with Reconstruction Including Robotic Endoscopic Surgery (MARRES): a prospective cohort study of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) and Korean Breast Cancer Study Group (KBCSG).
    Ryu JM; Lee J; Lee J; Ko B; Kim JH; Shin H; Park HS;
    BMC Cancer; 2023 Jun; 23(1):571. PubMed ID: 37344780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis.
    Metcalfe K; Huzarski T; Gronwald J; Kotsopoulos J; Kim R; Moller P; Pal T; Aeilts A; Eisen A; Karlan B; Bordeleau L; Tung N; Olopade O; Zakalik D; Singer CF; Foulkes W; Couch F; Neuhausen SL; Eng C; Sun P; Lubinski J; Narod SA;
    Br J Cancer; 2024 Feb; 130(2):269-274. PubMed ID: 38030749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
    Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
    Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
    Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
    Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
    Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
    Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
    Grinstein O; Krug B; Hellmic M; Siedek F; Malter W; Burke C; Schmutzler R; Maintz D; Rhiem K
    Surg Oncol; 2019 Jun; 29():126-133. PubMed ID: 31196476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.